Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 212

1.

Circulating levels of miR-7, miR-152 and miR-192 respond to vitamin D supplementation in adults with prediabetes and correlate with improvements in glycemic control.

Nunez Lopez YO, Pittas AG, Pratley RE, Seyhan AA.

J Nutr Biochem. 2017 Nov;49:117-122. doi: 10.1016/j.jnutbio.2017.08.007. Epub 2017 Aug 26.

PMID:
28945992
2.

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).

Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, Barner Lekdorf J, Kvist K, Buse JB; DEVOTE Study Group.

Diabetologia. 2018 Jan;61(1):48-57. doi: 10.1007/s00125-017-4423-z. Epub 2017 Sep 15.

PMID:
28913575
3.

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.

Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J, Lehmann L, Kvist K, Buse JB; DEVOTE Study Group.

Diabetologia. 2018 Jan;61(1):58-65. doi: 10.1007/s00125-017-4422-0. Epub 2017 Sep 15.

PMID:
28913543
4.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

PMID:
28854085
5.

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes.

Pratley RE, Cersosimo E.

Clin Diabetes. 2017 Jul;35(3):141-153. doi: 10.2337/cd16-0063.

PMID:
28761216
6.

Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM).

Heller SR, Pratley RE, Sinclair A, Festa A, Kiljański J, Brusko CS, Duan R, Heine RJ.

Diabetes Obes Metab. 2018 Jan;20(1):148-156. doi: 10.1111/dom.13051. Epub 2017 Aug 8.

PMID:
28671753
7.

Biopsychosocial Aspects of Weight Management in Type 1 Diabetes: a Review and Next Steps.

Driscoll KA, Corbin KD, Maahs DM, Pratley R, Bishop FK, Kahkoska A, Hood KK, Mayer-Davis E; Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON).

Curr Diab Rep. 2017 Aug;17(8):58. doi: 10.1007/s11892-017-0892-1. Review.

PMID:
28660565
8.

Postgastric bypass hypoglycaemia in a patient with end-stage renal disease: a diagnostic and management pitfall.

Khalid S, Bilal A, Asad-Ur-Rahman FNU, Pratley R.

BMJ Case Rep. 2017 Jun 15;2017. pii: bcr-2017-220600. doi: 10.1136/bcr-2017-220600.

PMID:
28619742
9.

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group.

N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.

PMID:
28605603
10.

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2017 Apr;40(4):e47-e48. doi: 10.2337/dci16-0048. No abstract available.

PMID:
28325804
11.

Inhibition of sweet chemosensory receptors alters insulin responses during glucose ingestion in healthy adults: a randomized crossover interventional study.

Karimian Azari E, Smith KR, Yi F, Osborne TF, Bizzotto R, Mari A, Pratley RE, Kyriazis GA.

Am J Clin Nutr. 2017 Apr;105(4):1001-1009. doi: 10.3945/ajcn.116.146001. Epub 2017 Mar 1.

PMID:
28251932
12.

SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial.

Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA; BARI-2D Study Group.

J Am Coll Cardiol. 2017 Jan 31;69(4):395-403. doi: 10.1016/j.jacc.2016.10.067.

PMID:
28126156
13.

Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?

Pratley RE.

Diabetes Technol Ther. 2016 Nov;18(11):671-673. No abstract available.

PMID:
27860501
14.

Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Frandsen KB, Rabøl R, Buse JB.

Am Heart J. 2016 Sep;179:175-83. doi: 10.1016/j.ahj.2016.06.004. Epub 2016 Jun 18.

15.

Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study.

Seyhan AA, Nunez Lopez YO, Xie H, Yi F, Mathews C, Pasarica M, Pratley RE.

Sci Rep. 2016 Aug 25;6:31479. doi: 10.1038/srep31479.

16.

Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2016 Oct;39(10):1684-92. doi: 10.2337/dc16-0798. Epub 2016 Jul 27.

17.

LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population.

Satman I, R Rea R, Eriksson M, Mosenzon O, Pratley R, M Baeres F, D Ørsted D, F Mann J; LEADER Trial Investigators.

J Diabetes Complications. 2016 Nov - Dec;30(8):1631-1639. doi: 10.1016/j.jdiacomp.2016.06.001. Epub 2016 Jun 3.

18.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

19.

Prognostic Value of Adipokines in Predicting Cardiovascular Outcome: Explaining the Obesity Paradox.

Wolk R, Bertolet M, Singh P, Brooks MM, Pratley RE, Frye RL, Mooradian AD, Rutter MK, Calvin AD, Chaitman BR, Somers VK; BARI 2D Study Group.

Mayo Clin Proc. 2016 Jul;91(7):858-66. doi: 10.1016/j.mayocp.2016.03.020. Epub 2016 Jun 9.

20.

Effects of glucose and insulin on secretion of amyloid-β by human adipose tissue cells.

Tharp WG, Gupta D, Smith J, Jones KP, Jones AM, Pratley RE.

Obesity (Silver Spring). 2016 Jul;24(7):1471-9. doi: 10.1002/oby.21494. Epub 2016 May 13.

Supplemental Content

Loading ...
Support Center